The Institute of NeuroPhysiopathology (INP) is a training and research centre of excellence that combines basic and translational research to study neural cell organisation, function and interaction, the molecular and cellular bases of major brain diseases, and to develop innovative cellular and molecular therapeutic strategies.
The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
We have a new preprint out! Want to do good super-resolution images? We have put together all our single molecule localization microscopy (SMLM) tips and tricks. This is a methods paper that describes our SMLM workflow, using benchmark samples such as microtubules and clathrin-coated pits.
Our latest work (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab (UW Madison, USA) and the Jung lab (Ohio University, USA) to reveal a new mechanism of slow axonal transport, based on our previous discovery of actin hotspots and trails.
Christophe was lucky to spend a whole week at the “Microscopie Fonctionnelle en Biologie” aka MiFoBio workshop. Lots of fun attending dozens of cutting-edge workshops, trying super-resolution microscopes, discussing, DJing (!), and presenting the latest work from the lab.
More on Twitter: #MiFoBio2018
The popularization of science is one of the missions of academic research. This article authored by Aurélie Soubéran is intended for children aged 12-13 years and more broadly for the general public, and focuses on a preclinical study on glioblastoma model.
To access it, please download the pdf version.
François Devred has presented his PINT/INP work on non-conventional use of nanoDSF in less than 180 seconds at the 3rd Arbre Mobieu plenary meeting in Zagreb.
See his flash presentation here and the meeting program on Arbre Mobieu website.
This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.
For more information, please follow this link or download the pdf version.
In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery into the brain and tumors".
For more information, please visit the symposium website or download the pdf version of the program.
In an interview published by "La Provence" on November 30, 2018 Yvon Bertrand, President of Aix-Marseille University, explains that AMU is very proud of its contribution to the field of Artificial Intelligence but also to the development of companies such as "First Light Imaging", VECT-HORUS or Innate-Pharma. They are real success stories from public research.
Maladie d'Alzheimer : une nouvelle année pleine d'espoir.
In its week-end edition (january the 4th & 5th 2020), the daily newspaper La Marseillaise devoted its "Provence Terre de Science" page to Alzheimer's disease reserach.
On this occasion François Devred (INP team 9 / PINT platform) answered a few questions on the molecular characterization of this complex protein (to be downloaded by clicking here )
First work of 2020 work is out for the NeuroCyto team! A collaboration with Matt Rasband’s lab in Nature Communications. This is a significant paper for the axon initial segment field: Matt’s lab used BioID of key AIS proteins for mapping AIS components. Dozens of new candidates for future studies! We performed super-resolution microscopy of several of the newly identified AIS components. IN particular, we showed that Mical3, a protein linking microtubules and actin, forms clusters along the AIS that are not periodically organized along the actin/spectrin scaffold.
If you speak French, you can listen to “La Méthode Scientifique”, a program on the France Culture radio which highlighted the recent Nature Communications article from the NeuroCyto team.
You can go to the audio clip by following this link and learn more on the France Culture website.
Our work on the ultrastructure of the periodic actin/spectrin scaffold along axons is out in Nature Communications.
In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).
We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.
- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.
On thursday december the 12th, most of INP and Vect-Horus members got together and spent a day in the Black Stone pub, Marseille, to celebrate the fact that nearly two years after its creation, the Institute of NeuroPhysiopathology is finally located on Tmone Campus.
Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).
Maeva and Noé presented their poster at the SFNano C'Nano conference entitled "Preclinical evaluation of a paclitaxel nanoprodrug for glioblastoma therapy".
L'équipe 5 a le plaisir d'accueillir en stage du 1er décembre 2019 au 31 mars 2020, Théo Loignon étudiant à l'école d'ingénieur de Bordeaux ei.cesi. Théo travaillera avec Jean-Philippe Dales sur l'imagerie chimique du tissu nerveux au cours de la neuroinflammation.
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Aix Marseille Université | All rights reserved - Legal notice
